Immunome
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.8 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 106.34% -4.81pp
- Institutions
- 252 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| Clay Siegall | Chairperson & CEO | 0.58% |
| Philip Wagenheim | Independent Director | 0.29% |
| Isaac Barchas | Lead Independent Director | 0.08% |
| Max Rosett | Chief Financial Officer | 0.05% |
| Jean-Jacques Bienaime | Independent Director | 0.04% |
| Philip Tsai | Chief Technology Officer | 0.04% |
| Jack Higgins | Chief Scientific Officer | 0.02% |
| Robert Lechleider | Chief Medical Officer | 0.01% |
| Sandra Stoneman | Chief Legal Officer | 0.00% |
| James Boylan | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Other Disposition | -4,000 | -- |
| 2026-09-10 | Jack Higgins | Chief Scientific Officer | Derivative Exercise and Sale | -18,000 | $1.35–25.32 |
| 2026-08-11 | Isaac Barchas | Lead Independent Director | Automatic Disposition | -11,048 | $27.25 |
| 2026-08-03 | Kinney Horn | Former Chief Business Officer | Derivative Exercise and Sale | -90,616 | $10.60–25.09 |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Acquisition | +180,000 | -- |
| 2026-07-22 | Clay Siegall | Chairperson & CEO | Other Derivative Acquisition | +360,000 | $22.01 |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Jack Higgins | Chief Scientific Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Acquisition | +54,000 | -- |
| 2026-07-22 | Robert Lechleider | Chief Medical Officer | Other Derivative Acquisition | +108,000 | $22.01 |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Sandra Stoneman | Chief Legal Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-22 | Kinney Horn | Former Chief Business Officer | Other Acquisition | +31,250 | -- |
| 2026-07-22 | Kinney Horn | Former Chief Business Officer | Other Derivative Acquisition | +62,500 | $22.01 |
| 2026-07-22 | Max Rosett | Chief Financial Officer | Other Acquisition | +47,250 | -- |
| 2026-07-22 | Max Rosett | Chief Financial Officer | Other Derivative Acquisition | +94,500 | $22.01 |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Acquisition | +38,250 | -- |
| 2026-07-22 | Philip Tsai | Chief Technology Officer | Other Derivative Acquisition | +76,500 | $22.01 |
| 2026-07-06 | Kinney Horn | Former Chief Business Officer | Derivative Exercise and Sale | -1,092 | $12.92–25.00 |
| 2026-07-01 | Robert Lechleider | Chief Medical Officer | Derivative Exercise and Sale | -55,000 | $8.73–23.44 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Immunome discussion 0 comments